Herpes simplex and vaccinia viruses and adenovirus types 1, 2, 5, and 7 were tested by plaque suppression methods for sensitivity to halogenated deoxyuridines (5-iodo-, 5-bromo-, 5-chloro-, and 5-fluoro-), cytosine arabinoside, isatin-f3-thiosemicarbazone, and N-methylisatin-,-thiosemicarbazone. After incubation for 12 days in HeLa cell cultures, vaccinia virus plaques were still readily suppressed by deoxyribonucleic acid (DNA) inhibitors and thiosemicarbazones. Herpes simplex virus plaques were likewise suppressed by at least three DNA inhibitors. Adenovirus plaques were not suppressed by DNA inhibitors or thiosemicarbazones. 5-Fluoro-2'-deoxyuridine could not be shown to have any antiviral activity, but it did produce a substantial lethal action on the cells.
Following the observation (9) that herpes simplex and vaccinia virus plaques could be suppressed by the deoxyribonucleic acid (DNA) inhibitors 5-bromo-and 5-iodo-2'-deoxyuridine (BUdR and IUdR), reports appeared indicating that these compounds also suppressed adenoviruses. IUdR was reported (16) to inhibit adenovirus type 5 , but a personal communication to the author (from R. R. Rafajko) indicated that it did not suppress other adenoviruses. Adenovirus type 5 was also reported to be inhibited by BUdR (13) ; however, even though a high level of this compound was used, the adenovirus-induced cytopathic effects could not be prevented. BUdR somewhat suppressed adenovirus type 12 (8) , but this compound alone could not eliminate the virus from cell cultures.
Cytosine arabinoside (1-f3-D-arabinofuranosylcytosine, ara-C) at a level of 100 ,g/ml was originally reported (3) to have no significant effect on the production of infectious adenovirus types 2, 3, 6, 8, and 10 . This was confirmed with adenovirus type 7 (6) ; further data were presented indicating that adenovirus type 7 was in fact suppressed by ara-C at 10 ,tg/ml (7). 5-Fluoro-2'-deoxyuridine (FUdR) has been shown to be highly active in suppressing adenovirus type 5 (13) ; so far as is known, however, there are no data on the antiviral effect of 5-chloro-2'-deoxyuridine (CUdR) in cell cultures. A report (2) has now appeared indicating that methisazone (Nmethylisatin-f-thiosemicarbazone), a potent inhibitor of poxviruses, is able to suppress Plates were incubated at room temperature for 2 hr with gentle agitation every 15 min. After this virus adsorption period, 14 ml of agar overlay medium (not over 42 C) was added to each plate. The overlay medium was also BME prepared as a twofold concentrate and then mixed with melted 2% Noble (Difco) agar. This medium was similar to that just described except that it was prepared from BME constituents obtained from Microbiological Associates, Inc. (Bethesda, Md.); therefore, for each liter of 2X medium, the following were mixed together: 200 ml of Earle's balanced salt solution (BSS), lOX concentrate, 20 ml of BME amino acid mixture, 20 ml of BME vitamin mixture, 15 ml of 0.2 N NaOH, 200 ml of fetal bovine serum, 20 ml of pH 7.6 Tris buffer, 30 ml of 7.5% sodium bicarbonate, and 20 ml of antibiotic stock solution (no phenol red). This mixture was then brought to 1 liter with distilled water.
Prior to use, 20 ml of Tryptose Phosphate Broth was added to each 100 ml of medium, and this combination was then mixed with 100 ml of melted agar; 2.2 ml of BME glutamine solution was added to each 220 ml of complete medium. This produced an overlay medium slightly more dilute than the growth medium described above.
The agar overlay was permitted to solidify for 15 to 20 min, and then antibiotic discs impregnated with test compounds were deposited in the center of each plate. The plates (6 to 10) were sealed in baking dishes and incubated at 36 C for 7 days; then 7 ml more of overlay medium was added to each plate, and the plates were resealed in baking dishes with fresh Saran Wrap and incubated for 5 more days. At the end of the 12-day incubation period, the plaques were determined by adding to each plate 7 ml of 2% Noble's agar containing 0.1% 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride (Aldrich Chemical, Milwaukee, Wis.). The placed on aluminum foil, dried at 36 C for 3 to 4 days, and then stored at 4 C until used.
RESULTS
Vaccinia virus plaques were readily suppressed by all test compounds except FUdR (Table 1) . From prior data, this was to be expected except this may be the first time CUdR has been shown to be active against vaccinia virus in vitro. In one sense, vaccinia virus was used as a control in these experiments, representing a DNA virus that is rather sensitive to all the test compounds. The fact that vaccinia virus plaques were suppressed throughout the entire test period indicates that all of the compounds retained a high degree of antiviral potency.
Herpes simplex virus also functioned as a sensitive virus control for at least three of the DNA inhibitors. As expected, the thiosemicarbazones did not affect this virus. IUdR clearly was more potent in suppressing herpes simplex virus plaques than those of vaccinia virus despite the higher dose of herpes simplex virus. BUdR also appeared to be more active on herpes simplex virus but the effect was not so great as observed with IUdR.
Data for the experiments with adenoviruses are compressed in Table 1 because, regardless of serotype or virus dose, the results were always consistent: no plaque-free zones were observed. In fact, adenovirus plaques occurred directly under No cellular toxicity was observed for any of the other compounds.
An additional attempt was made to detect an antiviral effect on adenoviruses by using the gradient plate method (15) . With what has been proved to be a substantial drug dose (44 ,ug/ml), no suppression of adenovirus plaques was obse*ved with serotypes 1, 2, and 5. Methisazone again in this test exhibited a toxicity effect on the cells, although it was by no means as severe as that seen with FUdR, which was lethal for HeLa cells at doses as low as 2 ,ug/ml.
It was observed, however, that certain DNA inhibitors did tend to reduce adenovirus plaque size in both the disc and the gradient plate tests. This was only seen at very high virus doses when confluent plaques were produced. Frequently, CUdR produced a recognizable zone where the plaques were somewhat smaller and confluency was therefore not present within the zone. On occasion, BUdR also had this effect; IUdR produced it rarely. This suggests that perhaps further study of this effect might lead to a rather sensitive plaque suppression method based on a minute decrease in plaque size.
DISCUSSION
It was not the intention of this study to determine whether the test compoundshad any antiviral effect at all on adenoviruses; rather, the purpose was to find how sensitive adenoviruses were when compared with vaccinia and herpes simplex viruses in a test widely used to screen for antiviral drugs. This comparison was especially pertinent with IUdR and methisazone, two drugs established as useful in man against smallpox, vaccinia, and herpes simplex virus infections. The data presented here would seem somewhat discouraging if any consideration were being given to the use of any of these compounds in adenovirus infections in man. IUdR has already been shown, in one clinical trial, to be ineffective in adenovirus conjunctivitis in volunteers (14) .
The rather low sensitivity of adenoviruses to DNA inhibitors may be the reason for a certain lack of agreement among investigators studying these compounds in adenovirus-infected liquid cell cultures. Recently, for example, with either IUdR or ara-C at a concentration of 40 ,moles/ ml, it was not possible to suppress adenovirus type 3 cytopathic effects in liquid cell culture (R. N. Appell, Abbott Laboratories, unpublished data). There was a small effect on intracellular virus production as well as some indication of a cellular toxic effect at this level of drug. It has already been suggested (11) that perhaps one method of in vitro testing of antiviral potency which might suggest potential usefulness of a drug in man is some form of the plaque-inhibition procedure. So far, all drugs with an antiviral effect in man are able to produce some significant plaque suppression (15) . Indeed, so can antibody (4) and interferon (17) . There are other correlations between the in vitro data presented here and certain in vivo results. For example, CUdR was not active in this study on herpes simplex virus and was also not very active in herpetic eye infections in rabbits (12) . So far as is known, FUdR has not been shown to be active in a herpes simplex virus plaque suppression test, even when the cells tolerate the toxic effects of this compound (10, 15) , and it has never been shown to be active in herpetic eye infections in animals (12) on October 25, 2017 by guest http://aem.asm.org/ Downloaded from
